News

Kirkland’s Regeneron-Novartis Roles Spark Disqualification Bid
Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
Is Regeneron Stock Undervalued At $500?
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
Why Regeneron Is Falling And Why You Should Avoid It
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
River Journal Online1d
Regeneron Outbid in Effort to Acquire 23andMe
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.
BioPharma Dive1d
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...